Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 495,925 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 495,925 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 264,932 | $0.00 Strike: $22.25 | $0.00 |
DisclosureSEC source: 0001562180-23-000221 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,932 Underlying: Common Stock · 264,932 shares Expires 2033-01-03 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 54,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000221 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,289 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 9,308 | $22.68 | $211,105.44 |
DisclosureSEC source: 0001562180-23-000221 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,536 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 170,188 | $0.00 Strike: $34.31 | $0.00 |
DisclosureSEC source: 0001562180-22-000149 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,188 Underlying: Common Stock · 170,188 shares Expires 2032-01-03 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 35,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000149 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,844 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 3,636 | $32.70 | $118,897.20 |
DisclosureSEC source: 0001562180-22-000149 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,048 Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GiftCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007473 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,684 F1 · shares: This transaction involved an irrevocable gift of securities by the Reporting Person to a charitable donor advised fund. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-21-006967 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,854 Underlying: Common Stock · 1,500 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,500 | $40.00 | $60,000.00 |
DisclosureSEC source: 0001562180-21-006967 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,500 | $3.76 | $5,640.00 |
DisclosureSEC source: 0001562180-21-006967 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-21-006147 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,354 Underlying: Common Stock · 1,500 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,500 | $42.19 | $63,285.00 |
DisclosureSEC source: 0001562180-21-006147 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,500 | $3.76 | $5,640.00 |
DisclosureSEC source: 0001562180-21-006147 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,854 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · derivative · entry 8 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,816 Underlying: Common Stock · 1,854 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 33,146 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · derivative · entry 7 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,854 Underlying: Common Stock · 33,146 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 35,000 | $45.11 | $1,578,850.00 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · nonDerivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.00 to $45.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,854 | $0.85 | $1,575.90 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 33,146 | $3.76 | $124,628.96 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · derivative · entry 6 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,000 | $40.02 | $120,060.00 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 3,000 | $3.76 | $11,280.00 |
DisclosureSEC source: 0001562180-21-005947 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-21-004525 · primarydocument.xml · derivative · entry 6 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,000 Underlying: Common Stock · 1,500 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,500 | $40.25 | $60,375.00 |
DisclosureSEC source: 0001562180-21-004525 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,500 | $3.76 | $5,640.00 |
DisclosureSEC source: 0001562180-21-004525 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-21-004525 · primarydocument.xml · derivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,500 Underlying: Common Stock · 4,500 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,500 | $40.02 | $180,090.00 |
DisclosureSEC source: 0001562180-21-004525 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,500 | $3.76 | $16,920.00 |
DisclosureSEC source: 0001562180-21-004525 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-21-001682 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,670 Underlying: Common Stock · 1,500 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,500 | $40.77 | $61,155.00 |
DisclosureSEC source: 0001562180-21-001682 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,500 | $0.85 | $1,275.00 |
DisclosureSEC source: 0001562180-21-001682 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-21-000562 · primarydocument.xml · derivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,170 Underlying: Common Stock · 6,500 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,211 | $44.99 | $234,442.89 |
DisclosureSEC source: 0001562180-21-000562 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $44.55 to $45.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 974 | $44.05 | $42,904.70 |
DisclosureSEC source: 0001562180-21-000562 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,195 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $43.55 to $44.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 315 | $42.64 | $13,431.60 |
DisclosureSEC source: 0001562180-21-000562 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,169 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $42.49 to $42.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 6,500 | $0.85 | $5,525.00 |
DisclosureSEC source: 0001562180-21-000562 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-21-000282 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,670 Underlying: Common Stock · 1,500 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,500 | $50.01 | $75,015.00 |
DisclosureSEC source: 0001562180-21-000282 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.095. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,500 | $0.85 | $1,275.00 |
DisclosureSEC source: 0001562180-21-000282 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:49 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 185,167 | $0.00 Strike: $44.97 | $0.00 |
DisclosureSEC source: 0001562180-21-000139 · primarydocument.xml · derivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,167 Underlying: Common Stock · 185,167 shares Expires 2031-01-04 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 4, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 13:49 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 40,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000139 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,984 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2022, January 1, 2023, January 1, 2024 and January 1, 2025 while the recipient provides continuous service to the Issuer. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-20-007506 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,170 Underlying: Common Stock · 6,500 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,853 | $49.16 | $91,093.48 |
DisclosureSEC source: 0001562180-20-007506 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $48.87 to $49.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,647 | $48.47 | $225,240.09 |
DisclosureSEC source: 0001562180-20-007506 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,853 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.87 to $48.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 6,500 | $0.85 | $5,525.00 |
DisclosureSEC source: 0001562180-20-007506 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-20-007469 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,670 Underlying: Common Stock · 4,500 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,500 | $50.00 | $225,000.00 |
DisclosureSEC source: 0001562180-20-007469 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,500 | $0.85 | $3,825.00 |
DisclosureSEC source: 0001562180-20-007469 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-20-007351 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,170 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,000 | $45.00 | $675,000.00 |
DisclosureSEC source: 0001562180-20-007351 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-20-007351 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.